Protea, Mayoly-Spindler conclude Phase I/II MS1819 trial
The trial was designed to investigate the safety profile of MS1819 and to get early evidence of the clinical activity of the MS1819 recombinant lipase in patients who
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.